Asphericity factor adjusted customised (F-CAT) vs topography-guided myopic ablation: contralateral eyes study evaluation

Session Details

Session Title: Presented Poster Session: Refractive Surgery New Techniques/Instrumentation/Devices III

Venue: Poster Village: Pod 2

First Author: : I.Kontari GREECE

Co Author(s): :    A. Kanellopoulos                       

Abstract Details

Purpose:

In this study we attempted to comparative evaluate safety and efficacy of Aspherisity Factor Adjusted Customized (F-CAT) vs. Topography-guided (T-CAT) myopic treatment.

Setting:

LaserVision.gr Clinical and Research Eye Institute, Athens, Greece

Methods:

Prospective randomized comparative case series study of 24 consecutive patients. One eye was randomly assigned to Aspherisity Factor Adjusted Customized (F-CAT) and the other contralateral eye of each patient to Topography-guided ablation. The FS200 femtosecond and EX500 excimer lasers were employed. Visual Acuity (Best Distance Visual Acuity and CDVA), measured optical zone, spherical equivalent refraction (SE), index of height decentration (IHD), and Q-value (@ 6- and 7- mm optical zone) were investigated preoperatively and postoperatively.


Results:

The best-corrected visual acuity (distance monocular) outcome shows that 91.66% of the eyes operated with F-CAT and 62.5% operated with T-CAT, had postoperative BCVA better than 1.0 (10/10). Postoperatively there was a significant increase over preoperatively “baseline” in the index of height decentration for the both groups (F-CAT: mean change 0.009±0.006, T-CAT: mean change 0.004±0.007). There was an increase in asphericity ΔQ = Qpost–Qpre and a moderate positive correlation between the preoperative and postoperative Q-value at 6 and 7mm OZ respectively, for the both groups.

Conclusions:

Contralateral comparison of Aspherisity Factor Adjusted Customized (F-CAT) vs. Topography-Guided myopic femtosecond treatments indicates that topography-guided treatments are statistically similar to F-CAT. Both F-CAT and Topography-Guided are considered viable options for customized myopic treatments.

Financial Disclosure:

None